Increase the proportion of Nabota-Pexclue-Enblo products
Operating profit of 49.6 billion won, up 37% year-on-year
Daewoong Pharmaceutical (CEO Lee Chang-jae and Park Sung-soo) announced that it recorded its best-ever performance in the second quarter with separate sales of KRW 325.5 billion and operating profit of KRW 49.6 billion. In particular, operating profit grew by 37.1% year-on-year, and the operating profit rate also recorded the highest ever at 15.2%.
Daewoong Pharmaceutical, which has grown into Korea’s number one ‘new drug development company’, has also significantly strengthened the stability of its financial structure by increasing the proportion of its own products centered on the three innovative new drugs, Nabota, Pexuclu, and Enblo.
![[헬스케어 소식] Daewoong Pharmaceutical, highest ever performance in Q2 with ‘3 major innovative new drugs’](https://dimg.donga.com/wps/NEWS/IMAGE/2024/08/13/126499073.7.jpg "[헬스케어 소식] Daewoong Pharmaceutical, highest ever performance in Q2 with ‘3 major innovative new drugs’")
Sales of Daewoong Pharmaceutical’s botulinum toxin product ‘Nabota’ reached an all-time high of KRW 53.1 billion, up 62% year-on-year.
The growth engine of Daewoong Pharmaceutical’s botulinum toxin is ‘global’. In the second quarter, the global export portion alone reached 85% of toxin sales. Daewoong Pharmaceutical’s botulinum toxin, which was approved as a ‘biological new drug’ by the US FDA, was launched in five countries, including the UK, Germany, Italy, Austria, and Spain, which account for 70% of the European market, after establishing itself as a ‘major toxin’ in the US market. It also recently entered the Oceania market with its launch in Australia.
The 34th domestic new drug, ‘Pexuclu’, recorded sales of 33.2 billion won in the second quarter, a 165% growth compared to the same period last year. It is changing the paradigm of the gastrointestinal medicine market by recording the highest growth rate among the P-CAB series gastroesophageal reflux disease treatment drugs. It is expected to continue its high growth in the second half of the year and achieve annual sales of 100 billion won this year.
The 36th domestic new drug, Enblo, continues to innovate by proving better effects than diabetes treatments from multinational pharmaceutical companies. It has surprised medical professionals and industry insiders at home and abroad by continuously announcing clinical results showing that it lowered blood sugar and glycated hemoglobin levels more than the multinational pharmaceutical company’s Dapagliflozin for diabetic patients with mild to moderate renal dysfunction. In the diabetes treatment market where multinational pharmaceutical companies were the mainstream, Daewoong Pharmaceutical’s domestic new drug Enblo is setting a new milestone.
Lee Chang-jae, CEO of Daewoong Pharmaceutical, said, “In a difficult environment with issues such as the global economic downturn, we achieved our best quarterly performance thanks to the high growth of Daewoong’s three innovative new drugs, Nabota, Pexuclu, and Enblo, while also significantly improving the stability of our financial structure.” He added, “We will continue to achieve high goals in the second half of the year and create an ‘innovative growth structure’ that renews growth every quarter.”
Reporter Yoo Ji-young [email protected]
Health
Lee Jin-young’s column
Jeong Do-eon’s Map of the Heart
Reporter Hong Eun-sim’s Ginga Min-ga Disease Signal
-
- great
- 0dog
-
- I’m sad
- 0dog
-
- I’m angry
- 0dog
-
- I recommend it
- dog
Hot news right now
2024-08-14 06:15:02